Abdul Zanabli, MD
Nephrology · S Charleston, WVNPI 1487752093
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,458 of the $30,727 with a category attached, or 66.6%. AstraZeneca accounts for 61.4% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $7,341 and has fallen 57.6% since, to $3,113 in 2025. Among nephrology clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 358 payments — averaging $85.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$19K
- Mallinckrodt Hospital Products Inc.$4K
- Otsuka America Pharmaceutical, Inc.$4K
- Travere Therapeutics, Inc.$516
- Bayer$507
- Vifor Pharma, Inc.$475
- plus $3K from 17 others
What the payments were for
- Consulting fees$2,2007%
- Speaking & faculty fees$20,45867%
- Travel & lodging$1931%
- Food & beverage$7,63925%
- Education$2371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 83 | $18,873 |
| Mallinckrodt Hospital Products Inc. | 39 | $4,329 |
| Otsuka America Pharmaceutical, Inc. | 46 | $3,502 |
| Travere Therapeutics, Inc. | 32 | $516 |
| Bayer | 24 | $507 |
| Vifor Pharma, Inc. | 18 | $475 |
| Amgen | 24 | $454 |
| Calliditas Therapeutics US Inc. | 17 | $369 |
| Novartis | 19 | $332 |
| Boehringer Ingelheim | 16 | $315 |
| Ardelyx, Inc. | 10 | $205 |
| Lilly USA, LLC | 8 | $171 |
| Axsome Therapeutics, Inc. | 1 | $122 |
| Recor Medical Inc | 4 | $104 |
| Fresenius USA Marketing, Inc. | 4 | $75 |
| Nxstage Medical, Inc. | 1 | $72 |
| OPKO Pharmaceuticals, LLC | 3 | $65 |
| ANI Pharmaceuticals, Inc. | 2 | $58 |
| Aurinia Pharma U.S., Inc. | 2 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $50 |
| GSK | 2 | $46 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,727 in reported general payments places this provider in the 95th percentile of 55 nephrology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 21 | $35,769 |
| Sevelamer Carbonate | 69 | $13,530 |
| Calcium Acetate | 12 | $1,098 |
| Megestrol Acetate | 17 | $882 |
| Hydralazine Hcl | 69 | $688 |
| Potassium Chloride | 18 | $461 |
| Calcitriol | 50 | $415 |
| Losartan Potassium | 61 | $361 |
| Doxazosin Mesylate | 12 | $321 |
| Metoprolol Succinate | 15 | $312 |
| Amlodipine Besylate | 36 | $239 |
| Torsemide | 14 | $182 |
| Furosemide | 22 | $108 |
| Clonidine Hcl | 24 | $103 |
| Carvedilol | 16 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $75 | $35,76921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 55 nephrology providers in West Virginia.
Other nephrology in S Charleston
- Julian EspirituSouth Charleston$215K
- Murad KheetanHuntington$25K
- Arijit ChakravartyMorgantown$19K
- Asif RahmanCharleston$8K
- Mirza HamiraniVienna$8K
- Michael CollinsHuntington$7K
- Khan ShabihCharleston$6K
- Faroug SulimanCharleston$6K
- Ahmad EterBeckley$5K
- Rebecca SchmidtMorgantown$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.